Last October 5th, in Spain, the Ministry of Health, Consumer Affairs and Social Welfare has approved funding in the National Health System for Angelini Pharma's cenobamate, a new anti-seizure medication (ASM). The product is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products1.
In Spain alone, it is estimated that 400,000 people suffer from epilepsy2, a chronic disease that affects more than 50 million people worldwide9. Approximately 40% of people with epilepsy continue to have seizures despite having been previously treated with two antiseizure medications1,3,4, indicating a high unmet need. The therapeutic goal of antiepileptic therapy is to achieve seizure freedom, yet the probability of achieving seizure freedom decreases with each failed treatment.
Olga Insua, Country Manager of Angelini Pharma Spain, declared: "The launch of cenobamate is not only great for all the people who suffer from epilepsy and, of course, for their families and the people who accompany them in their daily lives, but it is also a great advance for all the agents involved in the management of the pathology".
References1. Ficha técnica Ontozry.